Tuesday, November 06, 2018 12:52:50 PM
Coincidence here people? Follow with me to the end:
Paramount Capital Inc. is an investment bank that specializes in the biotechnology industry. The firm specifically seeks investments in the pharmaceutical, medical, and biotechnology areas.
What's the point? Well, the same Chief Compliance Officer of Paramount back then was the guy in the same role at Paulson Investment Company now:
Basil Christakos
Chief Compliance Officer
Basil Christakos is our Chief Compliance Officer at Paulson Investment Company, LLC. He has been involved in the securities industry for over 21 years and has held various roles within Compliance and Supervision at firms such as Clark Dodge & Co, Inc., Advanced Equities, Inc., and Paramount BioCapital, Inc. Basil has also represented many firms during regulatory examinations. He is experienced in coordinated private placement offerings for public and private issuers.
He has also performed the compliance function for a registered investment advisor and has skillfully facilitated the marketing of alternative investments.
His previous job per LinkedIn was:
Chief Compliance Officer
Company Name Paramount BioCapital, Inc.
Dates Employed May 2002 – Jun 2008
Employment Duration 6 yrs 2 mos
These are not strangers to our space people. The key officers know what to look for in a biotech and they "SKILLFULLY FACILITATE" investing in them. Good luck to the bruised longs but remain CaverStem rigid if you consider the fundamentals to be as strong as ever and find it curious that leading investment bankers are starting to grace our CELZy's doorway.
P.S. ONLY ~ 5 MORE TRADING DAYS UNTIL 10Q SHOULD ARRIVE!!!!!!!!!!!!
P.S.S. On 6/5/2018 two weeks after AUA and Q1 10Q, Celz was $0.0102. Then it was $0.07 on 6/28/2018. The DIFFERENCE 23 days can make with this thing.
P.S.S.S On 4/3/2018 the low was $0.0048. Then it was $0.0283 on 4/30/2018. WILD facts, aren't they? Things can change fast around here...don't you forget it.
All my posts are my opinions NOT INVESTMENT ADVICE. Also, my opinions only get to be made once a day because I like facts and I like to share them with my CELZ friends. -- Do your own DD on this ticker!
-- Narrow is the way and few are those who find it. --
Recent CELZ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM